Thus, in the case of LMP inducers, higher doses or targeting both the CSC and the more differentiated bulk tumor cells (e.g., with gemcitabine) would likely be necessary to achieve sustained tumor clearance. The gene discussed is PDLIM7; the disease is neoplasm.